Search

A series of variously functionalized selenium-containing compounds were purposely synthesized and evaluated against a panel of cancer cell lines. Most of the compounds showed an interesting cytotoxicity profile with compound 5 showing a potent activity on MCF7 cells. The ethyl amino derivative 5 acts synergistically with cis-platin and inhibits the GST enzyme with a potency that well correlates with the cytotoxicity observed in MCF7 cells. A computational analysis suggests a possible binding mode on the GST enzyme. As the main outcome of the present study, the ethyl amino derivative 5 emerged as a valid lead compound for further, future developments.

Abstract Nowadays, an efficient and robust virtual screening procedure is crucial in the drug discovery process, especially when performed on large and chemically diverse databases. Virtual screening methods, like molecular docking and classic QSAR models, are limited in their ability to handle vast numbers of compounds and to learn from scarce data, respectively. In this study, we introduce a universal methodology that uses a machine learning-based approach to predict docking scores without the need for time-consuming molecular docking procedures. The developed protocol yielded 1000 times faster binding energy predictions than classical docking-based screening. The proposed predictive model learns from docking results, allowing users to choose their preferred docking software without relying on insufficient and incoherent experimental activity data. The methodology described employs multiple types of molecular fingerprints and descriptors to construct an ensemble model that further reduces prediction errors and is capable of delivering highly precise docking score values for monoamine oxidase ligands, enabling faster identification of promising compounds. An extensive pharmacophore-constrained screening of the ZINC database resulted in a selection of 24 compounds that were synthesized and evaluated for their biological activity. A preliminary screen discovered weak inhibitors of MAO-A with a percentage efficiency index close to a known drug at the lowest tested concentration. The approach presented here can be successfully applied to other biological targets as target-specific knowledge is not incorporated at the screening phase.

Taurine is the most abundant non-proteinogenic sulphur amino acid in humans, and its level decreases dramatically with aging. In humans, the highest levels of taurine are present in retina, leukocytes, heart, skeletal muscles and brain. Taurine is necessary to ensure proper homeostasis and recent research in animals (for example mice and monkeys) have shown that it significantly increases life expectancy and improves health. At the cellular level, taurine is involved in a number of processes such as osmoregulation, modulation of calcium levels and stabilization of cell membranes. Moreover, it has an inhibitory effect on the central nervous system and has antioxidant, anti-apoptotic and anti-inflammatory activity. The development of neurodegenerative diseases is associated with improper functioning of mitochondria, oxidative stress, development of inflammation, excessive activation of ionotropic and metabotropic glutamate receptors and neuronal apoptosis. In vitro and in vivo studies have shown that taurine inhibits the above-mentioned pathological processes and has neuroprotective properties. The antioxidant effect of taurine results from neutralizing hypochlorous acid, a strong oxidant that is produced by neutrophils at the site of the inflammation. Taurine chloramine (Tau-Cl) produced in this reaction reduces oxidative stress and inhibits the production of pro-inflammatory cytokines (e.g. TNF-α, IL-1β, IL-6), nitric oxide (NO) and prostaglandin E2. Moreover, this compound stimulates the expression of antioxidant enzymes (e.g. peroxiredoxin 1, thioredoxin-1, hemooxygenase-1, glutathione peroxidase, catalase). Within the nervous tissue, the anti-inflammatory and antioxidant effect of taurine is related to reduced expression of IL-1α, IL-1β, TNF-α, IFN-γ, IL-6 and GM-CSF, and increase in the activity of antioxidant enzymes (peroxidase-, reductase- and S- glutathione transferase, superoxide dismutase) and glutathione concentration. Taurine is necessary for the proper functioning of mitochondria. Its deficiency blocks the synthesis of taurine-modified leucine tRNA (τm5U-tRNALeu), which results in inhibition of the synthesis of NADH-ubiquinone oxidoreductase, improper functioning of complex I of the respiratory chain and increase in oxidative stress. Endoplasmic reticulum (ER) stress is a hallmark of neurodegenerative diseases and can lead to neuronal apoptosis. Taurine deficiency increases the accumulation of misfolded cellular proteins and induces ER stress. Taurine supplementation reduces neuronal ER stress by inhibiting ATF6- and IRE-1-dependent signalling pathways. Moreover, taurine inhibits apoptosis of neuronal cells by increasing the expression of Bcl-2, decreasing the expression of p53, CHOP and Bax and reducing the activity of caspase-3. In the central nervous system, taurine also serves as an inhibitory neurotransmitter due to binding with γ-aminobutyric acid and glycine receptors (GABAA and GlyR, respectively). Such interactions causes an increased influx of chloride ions into neurons, hyperpolarization of the cell membrane and, consequently, inhibition of glutamatergic neurotransmission and excitotoxicity induced by glutamic acid. The neuroprotective activity of taurine is due to its pleiotropic effects related to the inhibition of apoptosis, oxidative stress, ER stress, and also to its anti-inflammatory activity and inhibition of neuronal excitability.

Polyunsaturated fatty acids, which include acids from the omega-3 and omega-6 groups, play an important role in the human body. The omega-3 family of acids includes α-linolenic acid (ALA), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). The main sources of α-linolenic acid in the diet are vegetable oils (the largest amounts are found in flax seed oil and chia oil), nuts, while docosahexaenoic and eicosapentaenoic acids are fish and marine algae. Omega-3 fatty acids (especially DHA) are crucial for proper prenatal brain development, as well as children's behavioral and intellectual development. This extremely important function of DHA is due to the stimulation of cellular processes important for proper neuronal development and function. High concentrations of DHA are found in the phospholipids of the retina, the membranes of brain-building cells, and are essential for normal vision as well as neuronal development. The neurotrophic and neuroprotective effects attributed to DHA may be related to the activity of DHA's metabolite N-docosahexaenoyl ethanolamine (synaptamide). Synaptamide (SA) is synthesized in the brain, retina, adipocytes or macrophages and is a more potent stimulator of synaptogenesis compared to DHA. The fetal demand for DHA is significantly increased during the third trimester of pregnancy. An important determinant of normal fetal blood levels of DHA is the mother's diet. In published studies, supplementation with omega-3 fatty acids has been shown to reduce the risk of pre-eclampsia and preterm labor. Pregnant women should consume adequate amounts of omega-3 fatty acids by providing them with their diet (e.g., vegetable oils, marine fish) and/or in the form of supplements (fish oil or preparations containing docosahexaenoic acid derived from marine algae. Higher intake of DHA-rich marine fish has been correlated with a lower incidence of postpartum depression in mothers. The aim of the article is to describe the biosynthesis, food sources and the recommended daily intake of DHA, with particular emphasis on pregnant women. In addition, the effects of DHA and synaptamide in the neurogenesis and their role in the proper functioning of the brain are discussed.

The classical low-molecular-weight drugs are designed to bind with high affinity to the biological targets endowed with receptor or enzymatic activity, and inhibit their function. However, there are many non-receptor or non-enzymatic disease proteins that seem undruggable using the traditional drug approach. This limitation has been overcome by PROTACs, bifunctional molecules that are able to bind the protein of interest and the E3 ubiquitin ligase complex. This interaction results in the ubiquitination of POI and subsequent proteolysis in the cellular proteasome. Out of hundreds of proteins serving as substrate receptors in E3 ubiquitin ligase complexes, current PROTACs recruit only a few of them, including CRBN, cIAP1, VHL or MDM-2. This review will focus on PROTACs recruiting CRBN E3 ubiquitin ligase and targeting various proteins involved in tumorigenesis, such as transcription factors, kinases, cytokines, enzymes, anti-apoptotic proteins and cellular receptors. The structure of several PROTACs, their chemical and pharmacokinetic properties, target affinity and biological activity in vitro and in vivo, will be discussed. We will also highlight cellular mechanisms that may affect the efficacy of PROTACs and pose a challenge for the future development of PROTACs.

A series of 3-benzylidenechrmanones 1, 3, 5, 7, 9 and their spiropyrazoline analogues 2, 4, 6, 8, 10 were synthesized. X-ray analysis confirms that compounds 2 and 8 crystallize in a monoclinic system in P21/n space groups with one and three molecules in each asymmetric unit. The crystal lattice of the analyzed compounds is enhanced by hydrogen bonds. The primary aim of the study was to evaluate the anti-proliferative potential of 3-benzylidenechromanones and their spiropyrazoline analogues towards four cancer cell lines. Our results indicate that parent compounds 1 and 9 with a phenyl ring at C2 have lower cytotoxic activity against cancer cell lines than their spiropyrazolines analogues. Analysis of IC50 values showed that the compounds 3 and 7 exhibited higher cytotoxic activity against cancer cells, being more active than the reference compound (4-chromanone or quercetin). The results of this study indicate that the incorporation of a pyrazoline ring into the 3-arylideneflavanone results in an improvement of the compounds’ activity and therefore it may be of use in the search of new anticancer agents. Further analysis allowed us to demonstrate the compounds to have a strong inhibitory effect on the cell cycle. For instance, compounds 2, 10 induced 60% of HL-60 cells to be arrested in G2/M phase. Using a DNA-cleavage protection assay we also demonstrated that tested compounds interact with DNA. All compounds at the concentrations corresponding to cytotoxic properties are not toxic towards red blood cells, and do not contribute to hemolysis of RBCs.

We identified novel dicarboximides that were selectively cytotoxic towards human leukemia cells. Using chemical and biological methods, we characterized the biological activity, identified cellular protein targets and defined the mechanism of action of the test dicarboximides. The reported IC50 values (concentration required to reduce cell survival fraction to 50% of control) of selected dicarboximides were similar or lower than IC50 of registered anticancer drugs, for example cytarabine, sorafenib, irinotecan. Test compounds induced apoptosis in chronic myelogenous (K562) and acute lymphoblastic (MOLT-4) leukemia cells by activation of receptor and mitochondrial apoptotic pathways and increased the expression of proapoptotic genes (BAX, NOXA, HTRA2, TNFRSF10B, ESRRBL1). Selected dicarboximides displayed immunomodulatory activity and downregulated IKZF1 and IKZF3 transcription factors in K562 and MOLT-4 leukemia cells. ATP-binding cassette protein 50 (ABC50) was identified as a target for dicarboximides. Cancer cells with knocked down ABC50 showed increased resistance to dicarboximides. Based on the structure of dicarboximides and thalidomide, novel proteolysis-targeting chimeras (PROTACs) were synthesized and used as tools to downregulate ABC50 in leukemia cells.

The results of our previous research indicated that some derivatives of benzofurans, particularly halogeno-derivatives, are selectively toxic towards human leukemia cells. Continuing our work with this group of compounds we here report new data on the synthesis as well as regarding the physico-chemical and biological characterization of fourteen new derivatives of benzofurans, including six brominated compounds. The structures of all new compounds were established by spectroscopic methods (1H- and, 13C-NMR, ESI MS), and elemental analyses. Their cytotoxicity was evaluated against K562 (leukemia), MOLT-4 (leukemia), HeLa (cervix carcinoma), and normal cells (HUVEC). Five compounds (1c, 1e, 2d, 3a, 3d) showed significant cytotoxic activity against all tested cell lines and selectivity for cancer cell lines. The SAR analysis (structure-activity relationship analysis) indicated that the presence of bromine introduced to a methyl or acetyl group that was attached to the benzofuran system increased their cytotoxicity both in normal and cancer cells.